Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation

被引:0
作者
Bohi, Flurina [1 ,2 ]
Hottiger, Michael O. [1 ]
机构
[1] Univ Zurich, Dept Mol Mech Dis, CH-8057 Zurich, Switzerland
[2] Univ Zurich, Life Sci Zurich Grad Sch, Canc Biol Ph D Program, CH-8057 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
PARP1; PARP inhibitors; immunomodulation; macrophages; T cells; cancer therapy; NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE-1; EXPRESSION; EFFICACY; CELLS; COACTIVATION; RESISTANCE; OLAPARIB; TUMORS;
D O I
10.3390/biomedicines12071617
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The emergence of PARP inhibitors as a therapeutic strategy for tumors with high genomic instability, particularly those harboring BRCA mutations, has advanced cancer treatment. However, recent advances have illuminated a multifaceted role of PARP1 beyond its canonical function in DNA damage repair. This review explores the expanding roles of PARP1, highlighting its crucial interplay with the immune system during tumorigenesis. We discuss PARP1's immunomodulatory effects in macrophages and T cells, with a particular focus on cytokine expression. Understanding these immunomodulatory roles of PARP1 not only holds promise for enhancing the efficacy of PARP inhibitors in cancer therapy but also paves the way for novel treatment regimens targeting immune-mediated inflammatory diseases.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
    Yamamoto, Tomomi M.
    Webb, Patricia G.
    Davis, Dana M.
    Baumgartner, Heidi K.
    Woodruff, Elizabeth R.
    Guntupalli, Saketh R.
    Neville, Margaret
    Behbakht, Kian
    Bitler, Benjamin G.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 647 - 657
  • [22] Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
    Robert, Carine
    Nagaria, Pratik K.
    Pawar, Nisha
    Adewuyi, Adeoluwa
    Gojo, Ivana
    Meyers, David J.
    Cole, Philip A.
    Rassool, Feyruz V.
    LEUKEMIA RESEARCH, 2016, 45 : 14 - 23
  • [23] Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
    Raspaglio, Giuseppina
    Buttarelli, Marianna
    Filippetti, Flavia
    Battaglia, Alessandra
    Buzzonetti, Alexia
    Scambia, Giovanni
    Gallo, Daniela
    CELL DEATH & DISEASE, 2021, 12 (10)
  • [24] Clinical importance of DNA repair inhibitors in cancer therapy
    Hosoya N.
    Miyagawa K.
    memo - Magazine of European Medical Oncology, 2009, 2 (1) : 9 - 14
  • [25] From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy
    Schreiber, Valerie
    Illuzzi, Giuditta
    Heberle, Elea
    Dantzer, Francoise
    BULLETIN DU CANCER, 2015, 102 (10) : 863 - 873
  • [26] Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions
    Ghelli Luserna di Rora, Andrea
    Jandoubi, Mouna
    Padella, Antonella
    Ferrari, Anna
    Marranci, Andrea
    Mazzotti, Cristina
    Olimpico, Francesco
    Ghetti, Martina
    Ledda, Lorenzo
    Bochicchio, Maria Teresa
    Paganelli, Matteo
    Zanoni, Michele
    Cafaro, Alessandro
    Servili, Chiara
    Galimberti, Sara
    Gottardi, Michele
    Rondoni, Michela
    Endri, Mauro
    Onofrillo, Daniela
    Audisio, Ernesta
    Marconi, Giovanni
    Simonetti, Giorgia
    Martinelli, Giovanni
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [27] Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases
    Pazzaglia, Simonetta
    Pioli, Claudio
    CELLS, 2020, 9 (01)
  • [28] EZH2 directly methylates PARP1 and regulates its activity in cancer
    Meng, Qingshu
    Shen, Jiangchuan
    Ren, Yanan
    Liu, Qi
    Wang, Rui
    Li, Qiaqia
    Jiang, Weihua
    Wang, Quan
    Zhang, Yixiang
    Trinidad, Jonathan C.
    Lu, Xiaotong
    Wang, Tingyou
    Li, Yanqiang
    Yum, Chaehyun
    Yi, Yang
    Yang, Yongyong
    Zhao, Dongyu
    Harris, Clair
    Kalantry, Sundeep
    Chen, Kaifu
    Yang, Rendong
    Niu, Hengyao
    Cao, Qi
    SCIENCE ADVANCES, 2024, 10 (48):
  • [29] Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors
    Mukhopadhyay, Asima
    Drew, Yvette
    Matheson, Elizabeth
    Salehan, Mo
    Gentles, Lucy
    Pachter, Jonathan A.
    Curtin, Nicola J.
    BIOCHEMICAL PHARMACOLOGY, 2019, 167 : 125 - 132
  • [30] PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
    McNevin, Ciara S.
    Cadoo, Karen
    Baird, Anne-Marie
    Finn, Stephen P.
    McDermott, Ray
    CANCERS, 2022, 14 (19)